Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), an American biotechnology company, on Monday announced that it planned to acquire 23andMe Holding Co.'s Personal Genome Service, Total Health ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Regeneron intends for 23andMe to continue its consumer genome services without interruption. The transaction, pending ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations. Regeneron Pharmaceuticals has announced an agreement to acquire all assets of 23andMe for $256 ...